Related Experiment Video
Updated: Dec 28, 2025
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized
Rajan Vijayaraghavan1, Ankur Jindal1, Vinod Arora1
1Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Insights
Adding simvastatin to carvedilol for primary prophylaxis in cirrhosis did not improve hemodynamic response. Close monitoring for simvastatin adverse effects is crucial, especially in Child C cirrhosis patients.
Area of Science:
- Hepatology
- Pharmacology
- Cardiology
Background:
- Beta-blockers are standard for reducing portal pressure and hepatic venous pressure gradient (HVPG) in cirrhosis.
- Primary prophylaxis aims to prevent variceal bleeding in cirrhotic patients.
- Carvedilol is a beta-blocker used for portal pressure reduction.
Purpose of the Study:
- To investigate if adding simvastatin to carvedilol improves hemodynamic response in cirrhotic patients undergoing primary prophylaxis.
- To compare the efficacy of carvedilol monotherapy versus carvedilol plus simvastatin in reducing HVPG.
- To assess secondary outcomes including variceal bleeding, mortality, and adverse events.
Main Methods:
- A prospective randomized study involving 220 cirrhotic patients with esophageal varices and HVPG > 12 mm Hg.
- Patients were randomized to receive either carvedilol alone (Group A) or carvedilol plus simvastatin (Group B).
- The primary endpoint was hemodynamic response (HVPG reduction ≥20% or <12 mm Hg) at 3 months.
Main Results:
- No significant difference in HVPG response rates between the carvedilol and carvedilol plus simvastatin groups (58.1% vs 61%, P=0.85).
- Mean HVPG reduction and hemodynamic response were comparable between groups.
- Simvastatin use was associated with transient elevations in liver enzymes and creatine phosphokinase in 3.7% of patients, resolving upon withdrawal. Bleeding and mortality rates were similar between groups.
Conclusions:
- Adding simvastatin to carvedilol for 3 months does not enhance hemodynamic response for primary prophylaxis of variceal bleeding compared to carvedilol monotherapy.
- Simvastatin should be used cautiously in Child C cirrhotic patients due to potential adverse effects.
- Achieving target heart rate without hypotension was associated with better hemodynamic response.
Introduction:
Beta-blockers are the mainstay agents for portal pressure reduction and to modestly reduce hepatic venous pressure gradient (HVPG). We studied whether addition of simvastatin to carvedilol in cirrhotic patients for primary prophylaxis improves the hemodynamic response.
Methods:
Cirrhotic patients with esophageal varices and with baseline HVPG > 12 mm Hg were prospectively randomized for primary prophylaxis to receive either carvedilol (group A, n = 110) or carvedilol plus simvastatin (group B, n = 110). Primary objective was to compare hemodynamic response (HVPG reduction of ≥20% or <12 mm Hg) at 3 months, and secondary objectives were to compare first bleed episodes, death, and adverse events.
Results:
The groups were comparable at baseline. The proportion of patients achieving HVPG response at 3 months was comparable between groups (group A-36/62 [58.1%], group B-36/59 [61%], P = 0.85). The degree of mean HVPG reduction (17.3% and 17.8%, respectively, P = 0.98) and hemodynamic response (odds ratio [OR]: 0.88; 95% confidence interval [CI]: 0.43-1.83, P = 0.74) was also not different between the groups. Patients who achieved target heart rate with no hypotensive episodes in either group showed better hemodynamic response (77.8% vs 59.2%, P = 0.04). Failure to achieve target heart rate (OR: 0.48; 95% CI: 0.22-1.06) and Child C cirrhosis (OR: 4.49; 95% CI: 1.20-16.8) predicted nonresponse. Three (3.7%) patients on simvastatin developed transient transaminitis and elevated creatine phosphokinase and improved with drug withdrawal. Two patients in each group bled (P = 0.99). Three patients and 1 patient, respectively, in group A and B died (P = 0.32), with sepsis being the cause of death.
Discussion:
Addition of simvastatin to carvedilol for 3 months for primary prophylaxis of variceal bleeding does not improve hemodynamic response over carvedilol monotherapy. Simvastatin usage should be closely monitored for adverse effects in Child C cirrhotic patients.
